{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:16:43Z","timestamp":1788221803793,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,14]]},"DOI":"10.7759\/cureus.31486","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T15:06:56Z","timestamp":1668438416000},"source":"Crossref","is-referenced-by-count":16,"title":["An Update on Treatment Options for Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Fatema","family":"Mahjabeen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utsow","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayesha  N","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eram","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan","family":"Fathma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Tasnim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridwan","family":"Faruq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Sakibuzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahmida","family":"Dilnaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrita","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1252-9","article-title":"Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice","volume":"18","author":"Harkins CP","year":"2017","unstructured":"Harkins CP, Pichon B, Doumith M, et al.. Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. Genome Biol. 2017, 18:130. 10.1186\/s13059-017-1252-9","journal-title":"Genome Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2019.1677607","article-title":"Emerging drugs for treating methicillin-resistant Staphylococcus aureus","volume":"24","author":"Bassetti M","year":"2019","unstructured":"Bassetti M, Russo A, Carnelutti A, Wilcox M. Emerging drugs for treating methicillin-resistant Staphylococcus aureus. Expert Opin Emerg Drugs. 2019, 24:191-204. 10.1080\/14728214.2019.1677607","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1442826","article-title":"Current and future treatment options for community-associated MRSA infection","volume":"19","author":"Khan A","year":"2018","unstructured":"Khan A, Wilson B, Gould IM. Current and future treatment options for community-associated MRSA infection. Expert Opin Pharmacother. 2018, 19:457-70. 10.1080\/14656566.2018.1442826","journal-title":"Expert Opin Pharmacother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01006-19","article-title":"Methicillin-resistant Staphylococcus aureus in hospitals: latest trends and treatments based on bacteriophages","volume":"57","author":"\u00c1lvarez A","year":"2019","unstructured":"\u00c1lvarez A, Fern\u00e1ndez L, Guti\u00e9rrez D, Iglesias B, Rodr\u00edguez A, Garc\u00eda P. Methicillin-resistant Staphylococcus aureus in hospitals: latest trends and treatments based on bacteriophages. J Clin Microbiol. 2019, 57:10.1128\/JCM.01006-19","journal-title":"J Clin Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0401-8","article-title":"Discovery of an antivirulence compound that reverses \u03b2-lactam resistance in MRSA","volume":"16","author":"El-Halfawy OM","year":"2020","unstructured":"El-Halfawy OM, Czarny TL, Flannagan RS, et al.. Discovery of an antivirulence compound that reverses \u03b2-lactam resistance in MRSA. Nat Chem Biol. 2020, 16:143-9. 10.1038\/s41589-019-0401-8","journal-title":"Nat Chem Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12743","article-title":"Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Lewis PO","year":"2018","unstructured":"Lewis PO, Heil EL, Covert KL, Cluck DB. Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Pharm Ther. 2018, 43:614-25. 10.1111\/jcpt.12743","journal-title":"J Clin Pharm Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2017-0199","article-title":"Strategies against methicillin-resistant Staphylococcus aureus persisters","volume":"10","author":"Kim W","year":"2018","unstructured":"Kim W, Hendricks GL, Tori K, Fuchs BB, Mylonakis E. Strategies against methicillin-resistant Staphylococcus aureus persisters. Future Med Chem. 2018, 10:779-94. 10.4155\/fmc-2017-0199","journal-title":"Future Med Chem"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01077-8","article-title":"Exploratory cost-effectiveness analysis for treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: is linezolid or daptomycin favored over vancomycin?","volume":"41","author":"Vu M","year":"2021","unstructured":"Vu M, Smith KJ, Aspinall SL, Clancy CJ, Buehrle DJ. Exploratory cost-effectiveness analysis for treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: is linezolid or daptomycin favored over vancomycin?. Clin Drug Investig. 2021, 41:885-94. 10.1007\/s40261-021-01077-8","journal-title":"Clin Drug Investig"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.02.006","article-title":"Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin","volume":"47","author":"Browne C","year":"2016","unstructured":"Browne C, Muszbek N, Chapman R, Marsh K, Gould IM, Seaton RA, Allen M. Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin. Int J Antimicrob Agents. 2016, 47:357-61. 10.1016\/j.ijantimicag.2016.02.006","journal-title":"Int J Antimicrob Agents"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu C","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al.. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011, 52:e18-55. 10.1093\/cid\/ciq146","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-016-0130-8","article-title":"Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE","volume":"15","author":"Seaton RA","year":"2016","unstructured":"Seaton RA, Gonzalez-Ruiz A, Cleveland KO, Couch KA, Pathan R, Hamed K. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob. 2016, 15:18. 10.1186\/s12941-016-0130-8","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour LM","year":"2015","unstructured":"Baddour LM, Wilson WR, Bayer AS, et al.. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015, 132:1435-86. 10.1161\/CIR.0000000000000296","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt396","article-title":"Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin","volume":"69","author":"Gasch O","year":"2014","unstructured":"Gasch O, Camoez M, Dom\u00ednguez MA, et al.. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother. 2014, 69:568-71. 10.1093\/jac\/dkt396","journal-title":"J Antimicrob Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2070","article-title":"Association of higher daptomycin dose (7 mg\/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"38","author":"Timbrook TT","year":"2018","unstructured":"Timbrook TT, Caffrey AR, Luther MK, Lopes V, LaPlante KL. Association of higher daptomycin dose (7 mg\/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy. 2018, 38:189-96. 10.1002\/phar.2070","journal-title":"Pharmacotherapy"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-014-0429-6","article-title":"High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it","volume":"16","author":"Smith JR","year":"2014","unstructured":"Smith JR, Claeys KC, Barber KE, Rybak MJ. High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. Curr Infect Dis Rep. 2014, 16:429. 10.1007\/s11908-014-0429-6","journal-title":"Curr Infect Dis Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00227-16","article-title":"Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"60","author":"Claeys KC","year":"2016","unstructured":"Claeys KC, Zasowski EJ, Casapao AM, et al.. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016, 60:5841-8. 10.1128\/AAC.00227-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.09.017","article-title":"Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC 1 mg\/l: a multicenter evaluation","volume":"38","author":"Moise PA","year":"2016","unstructured":"Moise PA, Culshaw DL, Wong-Beringer A, et al.. Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC 1 mg\/l: a multicenter evaluation. Clin Ther. 2016, 38:16-30. 10.1016\/j.clinthera.2015.09.017","journal-title":"Clin Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv076","article-title":"Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13)","volume":"70","author":"Sader HS","year":"2015","unstructured":"Sader HS, Farrell DJ, Flamm RK, Jones RN. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). J Antimicrob Chemother. 2015, 70:2053-6. 10.1093\/jac\/dkv076","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku455","article-title":"Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia","volume":"70","author":"Espedido BA","year":"2015","unstructured":"Espedido BA, Jensen SO, van Hal SJ. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia. J Antimicrob Chemother. 2015, 70:797-801. 10.1093\/jac\/dku455","journal-title":"J Antimicrob Chemother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00468-20","article-title":"The emerging role of \u03b2-lactams in the treatment of methicillin-resistant staphylococcus aureus bloodstream infections","volume":"64","author":"Molina KC","year":"2020","unstructured":"Molina KC, Morrisette T, Miller MA, Huang V, Fish DN. The emerging role of \u03b2-lactams in the treatment of methicillin-resistant staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2020, 64:10.1128\/AAC.00468-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-13","article-title":"\u03b2-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone","volume":"58","author":"Dilworth TJ","year":"2014","unstructured":"Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, Mercier RC. \u03b2-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother. 2014, 58:102-9. 10.1128\/AAC.01204-13","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2034","article-title":"Early administration of adjuvant \u03b2-lactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, multicenter analysis","volume":"37","author":"Casapao AM","year":"2017","unstructured":"Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ. Early administration of adjuvant \u03b2-lactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, multicenter analysis. Pharmacotherapy. 2017, 37:1347-56. 10.1002\/phar.2034","journal-title":"Pharmacotherapy"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis JS","year":"2016","unstructured":"Davis JS, Sud A, O'Sullivan MV, et al.. Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016, 62:173-80. 10.1093\/cid\/civ808","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong SY","year":"2020","unstructured":"Tong SY, Lye DC, Yahav D, et al.. Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020, 323:527-37. 10.1001\/jama.2020.0103","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2437","article-title":"Combination of vancomycin or daptomycin and beta-lactam antibiotics: a meta-analysis","volume":"40","author":"Kale-Pradhan PB","year":"2020","unstructured":"Kale-Pradhan PB, Giuliano C, Jongekrijg A, Rybak MJ. Combination of vancomycin or daptomycin and beta-lactam antibiotics: a meta-analysis. Pharmacotherapy. 2020, 40:648-58. 10.1002\/phar.2437","journal-title":"Pharmacotherapy"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2020.0350","article-title":"Vancomycin or daptomycin plus a \u03b2-lactam versus vancomycin or daptomycin alone for methicillin-resistant Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis","volume":"27","author":"Yi YH","year":"2021","unstructured":"Yi YH, Wang JL, Yin WJ, Xu WH. Vancomycin or daptomycin plus a \u03b2-lactam versus vancomycin or daptomycin alone for methicillin-resistant Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. Microb Drug Resist. 2021, 27:1044-56. 10.1089\/mdr.2020.0350","journal-title":"Microb Drug Resist"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.07.024","article-title":"Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","author":"Paladino JA","year":"2014","unstructured":"Paladino JA, Jacobs DM, Shields RK, et al.. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents. 2014, 44:557-63. 10.1016\/j.ijantimicag.2014.07.024","journal-title":"Int J Antimicrob Agents"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.104915","article-title":"Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: a comprehensive review","volume":"156","author":"Liu WT","year":"2021","unstructured":"Liu WT, Chen EZ, Yang L, Peng C, Wang Q, Xu Z, Chen DQ. Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: a comprehensive review. Microb Pathog. 2021, 156:104915. 10.1016\/j.micpath.2021.104915","journal-title":"Microb Pathog"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura M","year":"2021","unstructured":"Tsutsuura M, Moriyama H, Kojima N, et al.. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis. 2021, 21:153. 10.1186\/s12879-021-05858-6","journal-title":"BMC Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00738-06","article-title":"Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria","volume":"51","author":"Mortin LI","year":"2007","unstructured":"Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother. 2007, 51:1787-94. 10.1128\/AAC.00738-06","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01414","article-title":"Evolution of multi-resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus causing persistent bacteremia","volume":"11","author":"Chen CJ","year":"2020","unstructured":"Chen CJ, Huang YC, Shie SS. Evolution of multi-resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus causing persistent bacteremia. Front Microbiol. 2020, 11:1414. 10.3389\/fmicb.2020.01414","journal-title":"Front Microbiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3934\/microbiol.2019.2.117","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) and anti-MRSA activities of extracts of some medicinal plants: A brief review","volume":"5","author":"Okwu MU","year":"2019","unstructured":"Okwu MU, Olley M, Akpoka AO, Izevbuwa OE. Methicillin-resistant Staphylococcus aureus (MRSA) and anti-MRSA activities of extracts of some medicinal plants: A brief review. AIMS Microbiol. 2019, 5:117-37. 10.3934\/microbiol.2019.2.117","journal-title":"AIMS Microbiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fux007","article-title":"Antibiotic resistance in Staphylococcus aureus. Current status and future prospects","volume":"41","author":"Foster TJ","year":"2017","unstructured":"Foster TJ. Antibiotic resistance in Staphylococcus aureus. Current status and future prospects. FEMS Microbiol Rev. 2017, 41:430-49. 10.1093\/femsre\/fux007","journal-title":"FEMS Microbiol Rev"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2009.02.031","article-title":"Daptomycin: mechanisms of action and resistance, and biosynthetic engineering","volume":"13","author":"Baltz RH","year":"2009","unstructured":"Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol. 2009, 13:144-51. 10.1016\/j.cbpa.2009.02.031","journal-title":"Curr Opin Chem Biol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuv008","article-title":"Bacterial membrane lipids: diversity in structures and pathways","volume":"40","author":"Sohlenkamp C","year":"2016","unstructured":"Sohlenkamp C, Geiger O. Bacterial membrane lipids: diversity in structures and pathways. FEMS Microbiol Rev. 2016, 40:133-59. 10.1093\/femsre\/fuv008","journal-title":"FEMS Microbiol Rev"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2017.12.002","article-title":"Differential daptomycin resistance development in Staphylococcus aureus strains with active and mutated gra regulatory systems","volume":"308","author":"M\u00fcller A","year":"2018","unstructured":"M\u00fcller A, Grein F, Otto A, et al.. Differential daptomycin resistance development in Staphylococcus aureus strains with active and mutated gra regulatory systems. Int J Med Microbiol. 2018, 308:335-48. 10.1016\/j.ijmm.2017.12.002","journal-title":"Int J Med Microbiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-2999-3","article-title":"Down-regulation of the two-component system and cell-wall biosynthesis-related genes was associated with the reversion to daptomycin susceptibility in daptomycin non-susceptible methicillin-resistant Staphylococcus aureus","volume":"36","author":"Iwata Y","year":"2017","unstructured":"Iwata Y, Satou K, Tsuzuku H, et al.. Down-regulation of the two-component system and cell-wall biosynthesis-related genes was associated with the reversion to daptomycin susceptibility in daptomycin non-susceptible methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 2017, 36:1839-45. 10.1007\/s10096-017-2999-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2011.07576.x","article-title":"Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids","volume":"80","author":"Ernst CM","year":"2011","unstructured":"Ernst CM, Peschel A. Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol Microbiol. 2011, 80:290-9. 10.1111\/j.1365-2958.2011.07576.x","journal-title":"Mol Microbiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067398","article-title":"Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates","volume":"8","author":"Bertsche U","year":"2013","unstructured":"Bertsche U, Yang SJ, Kuehner D, et al.. Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. PLoS One. 2013, 8:e67398. 10.1371\/journal.pone.0067398","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2010.07464.x","article-title":"A role for the essential YycG sensor histidine kinase in sensing cell division","volume":"79","author":"Fukushima T","year":"2011","unstructured":"Fukushima T, Furihata I, Emmins R, Daniel RA, Hoch JA, Szurmant H. A role for the essential YycG sensor histidine kinase in sensing cell division. Mol Microbiol. 2011, 79:503-22. 10.1111\/j.1365-2958.2010.07464.x","journal-title":"Mol Microbiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01936-06","article-title":"YycH and YycI interact to regulate the essential YycFG two-component system in Bacillus subtilis","volume":"189","author":"Szurmant H","year":"2007","unstructured":"Szurmant H, Mohan MA, Imus PM, Hoch JA. YycH and YycI interact to regulate the essential YycFG two-component system in Bacillus subtilis. J Bacteriol. 2007, 189:3280-9. 10.1128\/JB.01936-06","journal-title":"J Bacteriol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00432-10","article-title":"VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus","volume":"56","author":"Mehta S","year":"2012","unstructured":"Mehta S, Cuirolo AX, Plata KB, et al.. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2012, 56:92-102. 10.1128\/AAC.00432-10","journal-title":"Antimicrob Agents Chemother"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026997","article-title":"Mechanism of action and resistance to daptomycin in Staphylococcus aureus and enterococci","volume":"6","author":"Miller WR","year":"2016","unstructured":"Miller WR, Bayer AS, Arias CA. Mechanism of action and resistance to daptomycin in Staphylococcus aureus and enterococci. Cold Spring Harb Perspect Med. 2016, 6:10.1101\/cshperspect.a026997","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.5512.2","article-title":"Diversity of two-component systems: insights into the signal transduction mechanism by the\u00a0 Staphylococcus aureus two-component system GraSR","volume":"3","author":"Muzamal U","year":"2014","unstructured":"Muzamal U, Gomez D, Kapadia F, Golemi-Kotra D. Diversity of two-component systems: insights into the signal transduction mechanism by the\u00a0 Staphylococcus aureus two-component system GraSR. F1000Res. 2014, 3:252. 10.12688\/f1000research.5512.2","journal-title":"F1000Res"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002359","article-title":"Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR","volume":"7","author":"Howden BP","year":"2011","unstructured":"Howden BP, McEvoy CR, Allen DL, et al.. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog. 2011, 7:e1002359. 10.1371\/journal.ppat.1002359","journal-title":"PLoS Pathog"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01303-15","article-title":"Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene","volume":"59","author":"B\u00e6k KT","year":"2015","unstructured":"B\u00e6k KT, Th\u00f8gersen L, Mogenssen RG, et al.. Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene. Antimicrob Agents Chemother. 2015, 59:6983-91. 10.1128\/AAC.01303-15","journal-title":"Antimicrob Agents Chemother"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028316","article-title":"Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus","volume":"7","author":"Peleg AY","year":"2012","unstructured":"Peleg AY, Miyakis S, Ward DV, et al.. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One. 2012, 7:e28316. 10.1371\/journal.pone.0028316","journal-title":"PLoS One"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000566","article-title":"Detection of high levels of resistance to linezolid and vancomycin in Staphylococcus aureus","volume":"66","author":"Azhar A","year":"2017","unstructured":"Azhar A, Rasool S, Haque A, Shan S, Saeed M, Ehsan B, Haque A. Detection of high levels of resistance to linezolid and vancomycin in Staphylococcus aureus. J Med Microbiol. 2017, 66:1328-31. 10.1099\/jmm.0.000566","journal-title":"J Med Microbiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review","volume":"4","author":"Cosimi RA","year":"2017","unstructured":"Cosimi RA, Beik N, Kubiak DW, Johnson JA. Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review. Open Forum Infect Dis. 2017, 4:ofx084. 10.1093\/ofid\/ofx084","journal-title":"Open Forum Infect Dis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q225","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"45","author":"Jorgenson MR","year":"2011","unstructured":"Jorgenson MR, DePestel DD, Carver PL. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ann Pharmacother. 2011, 45:1384-98. 10.1345\/aph.1Q225","journal-title":"Ann Pharmacother"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2007.00095.x","article-title":"Penicillin-binding proteins and beta-lactam resistance","volume":"32","author":"Zapun A","year":"2008","unstructured":"Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev. 2008, 32:361-85. 10.1111\/j.1574-6976.2007.00095.x","journal-title":"FEMS Microbiol Rev"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick K","year":"2010","unstructured":"Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010, 54:1670-7. 10.1128\/AAC.00019-10","journal-title":"Antimicrob Agents Chemother"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku114","article-title":"Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective","volume":"69","author":"Alm RA","year":"2014","unstructured":"Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother. 2014, 69:2065-75. 10.1093\/jac\/dku114","journal-title":"J Antimicrob Chemother"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis S","year":"2019","unstructured":"Weis S, Kesselmeier M, Davis JS, et al.. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2019, 25:818-27. 10.1016\/j.cmi.2019.03.010","journal-title":"Clin Microbiol Infect"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.2018.1435128","article-title":"Morbidity, mortality, and management of methicillin-resistant S. aureus bacteremia in the USA: update on antibacterial choices and understanding","volume":"46","author":"Ortwine JK","year":"2018","unstructured":"Ortwine JK, Bhavan K. Morbidity, mortality, and management of methicillin-resistant S. aureus bacteremia in the USA: update on antibacterial choices and understanding. Hosp Pract (1995). 2018, 46:64-72. 10.1080\/21548331.2018.1435128","journal-title":"Hosp Pract (1995)"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1596","article-title":"Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin","volume":"35","author":"Varada NL","year":"2015","unstructured":"Varada NL, Sakoulas G, Lei LR, Chua J. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. Pharmacotherapy. 2015, 35:608-12. 10.1002\/phar.1596","journal-title":"Pharmacotherapy"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01471-15","article-title":"Neutropenia associated with long-term ceftaroline use","volume":"60","author":"LaVie KW","year":"2016","unstructured":"LaVie KW, Anderson SW, O'Neal HR Jr, Rice TW, Saavedra TC, O'Neal CS. Neutropenia associated with long-term ceftaroline use. Antimicrob Agents Chemother. 2016, 60:264-9. 10.1128\/AAC.01471-15","journal-title":"Antimicrob Agents Chemother"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1435","article-title":"High incidence of discontinuations due to adverse events in patients treated with ceftaroline","volume":"34","author":"Jain R","year":"2014","unstructured":"Jain R, Chan JD, Rogers L, Dellit TH, Lynch JB, Pottinger PS. High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Pharmacotherapy. 2014, 34:758-63. 10.1002\/phar.1435","journal-title":"Pharmacotherapy"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek KJ","year":"2016","unstructured":"Furtek KJ, Kubiak DW, Barra M, Varughese CA, Ashbaugh CD, Koo S. High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother. 2016, 71:2010-3. 10.1093\/jac\/dkw062","journal-title":"J Antimicrob Chemother"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.03.008","article-title":"Adverse drug reactions associated with ceftaroline use: a 2-center retrospective cohort","volume":"4","author":"Blumenthal KG","year":"2016","unstructured":"Blumenthal KG, Kuhlen JL Jr, Weil AA, Varughese CA, Kubiak DW, Banerji A, Shenoy ES. Adverse drug reactions associated with ceftaroline use: a 2-center retrospective cohort. J Allergy Clin Immunol Pract. 2016, 4:740-6. 10.1016\/j.jaip.2016.03.008","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak M","year":"2019","unstructured":"Geriak M, Haddad F, Rizvi K, et al.. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019, 63:10.1128\/AAC.02483-18","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/119322-an-update-on-treatment-options-for-methicillin-resistant-staphylococcus-aureus-mrsa-bacteremia-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:42:03Z","timestamp":1707507723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/119322-an-update-on-treatment-options-for-methicillin-resistant-staphylococcus-aureus-mrsa-bacteremia-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":61,"URL":"https:\/\/doi.org\/10.7759\/cureus.31486","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,14]]}}}